Hypertension
Conditions
Interventions
Intervention Switching ACE-I or ARB to aliskiren
Intervention Poor blood pressure control Add aliskiren to conventional anti-hypertensive therapy with ACE-I or ARB
Control Conventional anti-hypert
Sponsors
Division of Cardiology, Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Anti-hypertensive treatment with ACE-I or ARB 2) Plasma aldosterone concetraion is greater than 100pg/ml 3) Without taking aldostetone blocker 4) 20 years and older 5) Only outpatient 6) Male and Female
Exclusion criteria
Exclusion criteria: 1)Left ventricular systolic dysfunction (LVEF is under 40% on echocardiography) 2)History of Acute coronary syndrome or stroke within 6 months 3)Serum Cr is over 2.0mg/dl 4)Serum potassium is over 5.0mmol/L 5)Hypertensivity or contraindication to aliskiren 6)Pregnancy or Breastfeeding 7)Inability to obtain informed consent 8)Any conditions not suitable for the participation in this trial judged by the investigator
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Changes in 24hr blood pressure Changes in left ventricular hypertrophy(electrocardiogram and echocardiography) | — |
Primary
| Measure | Time frame |
|---|---|
| Plasma aldosterone concentration Improvement of hypertensive target organ damage measured as urinary albumin excretion ratio | — |
Countries
Japan
Contacts
Public ContactTomohiro Matsuhashi, Motoaki Sano
Keio University School of Medicine Division of Cardiology
Outcome results
None listed